UF startup Dialectic Therapeutics, Inc., a clinical-stage biotechnology company developing innovative anti-cancer drugs, announced that patient dosing is underway in a clinical trial led by the renowned Drs. Elizabeth Stover, Joyce Liu, and Ursula Matulonis from the Dana-Farber Cancer Institute. Dr. Matulonis previously served as the Principal Investigator for the study that led to a recent FDA approval in platinum-resistant ovarian cancer (PROC).
Read more about Dialectic Therapeutics Announces Dosing of First Patient in Platinum-Resistant Ovarian Cancer (PROC).
